ArticleJournal of virology2026
Neurotropism and interferon-dominated immune responses in a mouse-adapted coxsackievirus A16 infection model.
Article in Journal of virology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The development of animal models infected with Coxsackievirus A16 (CVA16) is limited by insufficient neurovirulence, which hinders the study of pathogenesis mechanisms and antiviral drug evaluation. Therefore, we aimed to develop a neonatal ICR mouse model for CVA16 infection, wherein infected brain tissue was continuously passaged from 2-day-old ICR suckling mice, resulting in a highly neurovirulent mouse-adapted strain (CVA16-P5) to establish optimal infection conditions for antiviral assessment. By systematically optimizing viral dose, inoculation route, and age at infection, we defined conditions that reproducibly induced progressive neurological disease and multisystem involvement. Infection with the CVA16-P5 strain resulted in consistent pathological alterations across multiple tissues, accompanied by characteristic neurological manifestations. Transcriptomic analysis of neural tissues revealed tissue-specific interferon-dominated immune responses and signatures of systemic viral dissemination that recapitulate key features of severe human infection. Whole-genome sequencing identified a nonsynonymous mutation in the VP1 capsid protein associated with enhanced neurovirulence during mouse adaptation. Overall, this CVA16-P5-adapted strain infection model provides a robust experimental platform for investigating CVA16 pathogenesis and for the preclinical evaluation of vaccines and antiviral drugs against neurotropic enteroviruses. IMPORTANCE: The lack of animal models that reliably recapitulate the neurological manifestations of Coxsackievirus A16 infection has constrained progress in understanding CVA16 neuropathogenesis. Here, we describe a neonatal mouse model based on a mouse-adapted CVA16 strain (CVA16-P5) that consistently induces neurological disease and multisystem pathology. This model enables the analysis of tissue-specific immune responses, viral dissemination, and genetic determinants of neurovirulence, including a VP1 mutation associated with enhanced pathogenicity. By providing a reproducible and physiologically relevant system for studying severe CVA16 infection, the CVA16-P5-adapted strain infection model setup in this study supports mechanistic studies of CVA16 pathogenesis and facilitates the preclinical evaluation of vaccines and antiviral drugs against neurotropic enteroviruses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.